 Fiona Zwald
Concepts (83)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 12 | 2021 | 756 | 2.370 |
Why?
| | Organ Transplantation | 7 | 2021 | 159 | 1.870 |
Why?
| | Carcinoma, Squamous Cell | 7 | 2021 | 577 | 1.280 |
Why?
| | Melanoma | 4 | 2021 | 620 | 1.140 |
Why?
| | Mohs Surgery | 2 | 2015 | 24 | 0.900 |
Why?
| | Transplants | 1 | 2020 | 36 | 0.690 |
Why?
| | Neoplasms, Second Primary | 1 | 2021 | 92 | 0.680 |
Why?
| | Neoplasm Recurrence, Local | 5 | 2020 | 858 | 0.530 |
Why?
| | Carcinoma, Merkel Cell | 1 | 2016 | 17 | 0.510 |
Why?
| | Dermatology | 1 | 2015 | 86 | 0.450 |
Why?
| | Curettage | 1 | 2013 | 9 | 0.440 |
Why?
| | Career Choice | 1 | 2015 | 177 | 0.440 |
Why?
| | Electrocoagulation | 1 | 2013 | 38 | 0.430 |
Why?
| | Faculty, Medical | 1 | 2015 | 228 | 0.420 |
Why?
| | Academic Medical Centers | 1 | 2015 | 411 | 0.410 |
Why?
| | Dermatofibrosarcoma | 1 | 2012 | 9 | 0.410 |
Why?
| | Carcinoma, Basal Cell | 1 | 2013 | 68 | 0.400 |
Why?
| | Histiocytoma, Malignant Fibrous | 1 | 2011 | 4 | 0.390 |
Why?
| | Histiocytoma, Benign Fibrous | 1 | 2011 | 6 | 0.390 |
Why?
| | Antifungal Agents | 1 | 2012 | 128 | 0.380 |
Why?
| | Triazoles | 1 | 2012 | 131 | 0.370 |
Why?
| | Pyrimidines | 2 | 2017 | 376 | 0.350 |
Why?
| | Lung Transplantation | 1 | 2012 | 246 | 0.340 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1395 | 0.300 |
Why?
| | Neoplasms | 1 | 2020 | 2097 | 0.270 |
Why?
| | Kidney Transplantation | 1 | 2011 | 541 | 0.260 |
Why?
| | Heart Transplantation | 1 | 2011 | 665 | 0.250 |
Why?
| | Liver Transplantation | 1 | 2011 | 707 | 0.240 |
Why?
| | Transplant Recipients | 2 | 2021 | 140 | 0.210 |
Why?
| | Keratosis, Actinic | 1 | 2021 | 11 | 0.190 |
Why?
| | Prognosis | 4 | 2020 | 3329 | 0.180 |
Why?
| | Humans | 18 | 2021 | 114689 | 0.180 |
Why?
| | Hematologic Neoplasms | 1 | 2020 | 137 | 0.160 |
Why?
| | Neoplasm Staging | 2 | 2018 | 1167 | 0.140 |
Why?
| | Chemoprevention | 1 | 2018 | 88 | 0.140 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2018 | 52 | 0.140 |
Why?
| | Janus Kinase Inhibitors | 1 | 2017 | 10 | 0.140 |
Why?
| | International Agencies | 1 | 2016 | 30 | 0.130 |
Why?
| | Risk Factors | 4 | 2018 | 8632 | 0.130 |
Why?
| | Private Practice | 1 | 2015 | 20 | 0.130 |
Why?
| | Professional Autonomy | 1 | 2015 | 25 | 0.120 |
Why?
| | Personnel Turnover | 1 | 2015 | 27 | 0.120 |
Why?
| | Salaries and Fringe Benefits | 1 | 2015 | 52 | 0.120 |
Why?
| | Immunocompromised Host | 2 | 2018 | 195 | 0.120 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2015 | 79 | 0.120 |
Why?
| | Workload | 1 | 2015 | 132 | 0.110 |
Why?
| | Pyrazoles | 1 | 2017 | 362 | 0.110 |
Why?
| | Research Personnel | 1 | 2015 | 149 | 0.110 |
Why?
| | Cooperative Behavior | 1 | 2015 | 381 | 0.100 |
Why?
| | Data Collection | 1 | 2015 | 620 | 0.100 |
Why?
| | Leadership | 1 | 2015 | 292 | 0.100 |
Why?
| | Voriconazole | 1 | 2012 | 24 | 0.100 |
Why?
| | Mycoses | 1 | 2012 | 67 | 0.100 |
Why?
| | Male | 6 | 2017 | 55599 | 0.090 |
Why?
| | Disease Progression | 1 | 2018 | 2380 | 0.090 |
Why?
| | Middle Aged | 4 | 2017 | 26737 | 0.090 |
Why?
| | Incidence | 2 | 2018 | 2313 | 0.080 |
Why?
| | Sentinel Lymph Node Biopsy | 1 | 2010 | 99 | 0.080 |
Why?
| | Attitude of Health Personnel | 1 | 2015 | 975 | 0.080 |
Why?
| | Consensus | 2 | 2020 | 537 | 0.080 |
Why?
| | Combined Modality Therapy | 1 | 2011 | 1121 | 0.070 |
Why?
| | Female | 3 | 2015 | 59511 | 0.050 |
Why?
| | Delphi Technique | 1 | 2021 | 160 | 0.050 |
Why?
| | Aged, 80 and over | 1 | 2011 | 6347 | 0.050 |
Why?
| | Aminoquinolines | 1 | 2018 | 20 | 0.040 |
Why?
| | Aged | 2 | 2017 | 19074 | 0.040 |
Why?
| | Capecitabine | 1 | 2018 | 45 | 0.040 |
Why?
| | Administration, Cutaneous | 1 | 2018 | 117 | 0.040 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2018 | 81 | 0.040 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2018 | 182 | 0.040 |
Why?
| | Neoplasm Grading | 1 | 2018 | 242 | 0.030 |
Why?
| | Lymphatic Metastasis | 1 | 2018 | 275 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2018 | 332 | 0.030 |
Why?
| | Sirolimus | 1 | 2018 | 181 | 0.030 |
Why?
| | Administration, Intravenous | 1 | 2017 | 124 | 0.030 |
Why?
| | Nitriles | 1 | 2017 | 149 | 0.030 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2018 | 194 | 0.030 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2018 | 152 | 0.030 |
Why?
| | Lymph Nodes | 1 | 2018 | 419 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2018 | 347 | 0.030 |
Why?
| | ErbB Receptors | 1 | 2018 | 554 | 0.030 |
Why?
| | Immunosuppressive Agents | 1 | 2018 | 646 | 0.030 |
Why?
| | Treatment Outcome | 1 | 2017 | 9088 | 0.010 |
Why?
|
|
Zwald's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|